Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Feb 27;96(6):896–902. doi: 10.1038/sj.bjc.6603648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

(A–D) Fluoro: fluoropyrimidines (fluorouracil, capecitabine, tegafur); Gem: gemcitabine; Platin: platinum compounds (cisplatin, oxaliplatin, carboplatin); Anthra: anthracyclines (adriamycin, epirubicin); MMC: mitomycin C; Taxan: taxanes (paclitaxel, docetaxel), Irino: irinotecan. (A) Pooled RRs (RR=CR+PR) and 95% CIs of all patients included in the analysis and of subgroups of patients, defined by treatment with regimens containing a particular drug regardless of other drugs. The height of the bars correlates with the number of patients. The P-values apply to the comparison of a subgroup, defined by a particular drug vs all other patients, which were not treated with this drug (e.g., patients treated with gemcitabine or gemcitabine-containing combinations vs patients treated with gemcitabine-free regimens). The RRs of the comparison subgroups are not shown. The vertical grey line represents the pooled RR of all patients (pts, 22.6%). (B) Boxplots of the RRs of all trials and of subgroups, defined by a particular drug. The height of the boxplots correlates with the number of trials. P-values for subgroup comparison as in Figure 3A. The vertical grey line represents the median RR of all trials (20.0%). For subgroups consisting of less than five trials, results of single trial are shown and no boxplots are provided. (C) Pooled TCRs (TCR=CR+PR+SD) and 95% CIs as in Figure 3A. The vertical grey line represents the pooled TCR of all patients (57.3%). (D) Boxplots of the TCRs as in Figure 3B. The vertical grey line represents the median TCR of all trials (59.6%).